Literature DB >> 33151370

Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.

Masato Aragaki1, Yasuhiro Hida2, Tatsuya Kato2, Aki Fujiwara-Kuroda2, Kichizo Kaga2, Satoru Wakasa2.   

Abstract

PURPOSE: This study aimed to establish new criteria for limited resection of non-small cell lung cancer (NSCLC) based on computed tomography findings and maximum standardized uptake value (SUVmax).
METHODS: Between December 2007 and December 2015, 611 patients underwent lung cancer surgery; of these, 70 with cT1aN0M0 who underwent limited resection were enrolled. Criteria for undergoing intentional limited resection (ILR) were (1) tumor ground-glass opacity (GGO) ratio of ≥ 0.75 and (2) tumor SUVmax ≤ 1.5. Patients who met criteria (1) and (2) underwent partial resection, and those who only met criteria (2) underwent segmentectomy as ILR. The control group was subjected to limited surgery without meeting the criteria.
RESULTS: Overall, 45 and 25 patients who met the criteria were included in the ILR and control groups, respectively. In the ILR group, 13 patients underwent partial resection, and 32 underwent segmentectomy; in the control group, 18 patients underwent partial resection and 7 underwent segmentectomy. According to our criteria, no relapsed cases occurred in the ILR group, although six patients showed recurrence of lung cancer in the control group. The 5-year overall survival (OS) rates in the ILR and control groups were 100% and 67.7%, respectively, and the relapse-free survival (RFS) rates were 100% and 61.6%, respectively. The log-rank test showed that this difference was statistically significant (OS: P < 0.0001, RFS: P < 0.0001).
CONCLUSIONS: SUVmax may serve as a predictive marker of recurrence to determine the treatment strategy for patients with NSCLC. Patients with low GGO ratio and low SUVmax may be cured by limited resection.

Entities:  

Keywords:  Limited resection; Non-small cell lung cancer; SUVmax; Segmentectomy

Mesh:

Year:  2020        PMID: 33151370     DOI: 10.1007/s00432-020-03441-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

Authors:  David S Ettinger; Douglas E Wood; Charu Aggarwal; Dara L Aisner; Wallace Akerley; Jessica R Bauman; Ankit Bharat; Debora S Bruno; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Scott Gettinger; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Jules Lin; Billy W Loo; Renato G Martins; Gregory A Otterson; Sandip P Patel; Karen L Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt W Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2019-12       Impact factor: 11.908

2.  Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules.

Authors:  Jong Ho Cho; Yong Soo Choi; Jhingook Kim; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim
Journal:  Ann Thorac Surg       Date:  2014-11-15       Impact factor: 4.330

3.  A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211).

Authors:  Keiju Aokage; Hisashi Saji; Kenji Suzuki; Tomonori Mizutani; Hiroshi Katayama; Taro Shibata; Syunichi Watanabe; Hisao Asamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-03-02

4.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

5.  Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study.

Authors:  Chenyang Dai; Jianfei Shen; Yijiu Ren; Shengyi Zhong; Hui Zheng; Jiaxi He; Dong Xie; Ke Fei; Wenhua Liang; Gening Jiang; Ping Yang; Rene Horsleben Petersen; Calvin S H Ng; Chia-Chuan Liu; Gaetano Rocco; Alessandro Brunelli; Yaxing Shen; Chang Chen; Jianxing He
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

6.  Segmental resection for bronchogenic carcinoma: a surgical alternative for the compromised patient.

Authors:  W F Bennett; R A Smith
Journal:  Ann Thorac Surg       Date:  1979-02       Impact factor: 4.330

7.  Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters.

Authors:  Go Akamatsu; Kaori Ishikawa; Katsuhiko Mitsumoto; Takafumi Taniguchi; Nobuyoshi Ohya; Shingo Baba; Koichiro Abe; Masayuki Sasaki
Journal:  J Nucl Med       Date:  2012-09-04       Impact factor: 10.057

8.  The role of the ground-glass opacity ratio in resected lung adenocarcinoma.

Authors:  Tsai-Wang Huang; Kuan-Hsun Lin; Hsu-Kai Huang; Yi-I Chen; Kai-Hsiung Ko; Cheng-Kuang Chang; Hsian-He Hsu; Hung Chang; Shih-Chun Lee
Journal:  Eur J Cardiothorac Surg       Date:  2018-08-01       Impact factor: 4.191

9.  A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions.

Authors:  Hisao Asamura; Kenji Suzuki; Shun-ichi Watanabe; Yoshihiro Matsuno; Arafumi Maeshima; Ryosuke Tsuchiya
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

Review 10.  Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Xiongfeng Huang; Jianmin Wang; Qiao Chen; Jielin Jiang
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.